
Trust closes amid funding woes
Regrettably the tank is empty, said Waiora Links Community Trust co-founder Ronel Stephens after the sudden decision to close it down last week.
''The decision has not been made lightly, but despite our best efforts, we have been unable to secure the operational funding needed to sustain our work.''
Stephens says without this crucial funding support, the trust had to rely solely on its remaining reserves to continue offering community favourites, such as the monthly cuppas, Anzac morning tea, January picnic, and trips to the Ohoka Market, all at little or no cost to the community.
The trust was officially formed early in December 2022, and its aim was to support community wellbeing in the growing Woodend, Ravenswood, Pegasus and Waikuku communities by running free events to help residents connect with one another.
Over the three years the trust has been responsible for hosting volunteer expos, Toot 4 Tucker, Pink Ribbon morning teas, end of year cuppas, community network meetings, public consultations, day trips to events and the community centre advisory group meetings in the Woodend, Pegasus and Waikuku areas.
Stephens said the trust formally thanks all of its volunteers, sponsors and funders, along with partner organisations.
''An invitation to our last event on June 11, is open to everyone. Please feel free to join us then.'
She said the Ronel's cuppa events have grown in popularity over the years, and was well supported by outside organisations in the form of representatives of those institutions doing presentations and talks at the cuppa.
However, she will no longer offer this event and the last Ronel's Community Cuppa will be on June 11. It will be the eighth anniversary and the last hooray.
Waimakariri Mayor Dan Gordon said he was saddened to hear about the closure of Waiora Links Community Trust.
''They've been fantastic at unifying their community, hosting events, fostering a real sense of place, and bringing people together.''
He said he has been a big fan of the Community Cuppas hosted by Ronel — ''the baking was always exceptional'' — and he regularly attended the many events the trust organised over the years.
''Their contributions will be missed.
''I know it wouldn't have been an easy decision to make, but it's important to celebrate the contributions that have been made over many years.''
Waimakariri district councillor Brent Cairns said he was also saddened by the closure.
''Look at the hole they are going to be leaving in the community, Ronel's Cuppa will be hugely missed.''
He said this should serve as a wake-up call about how people in Waimakariri rely so heavily on volunteer groups and organisations.
''They work for so many organisations, without pay and giving of their free time to help others. This is what happens when they want to step back, to step out of the limelight and they have done their time and want to move on, so what happens next?''
He says funding is always a major concern for the many large and small volunteer groups in the community.
''What are other groups doing as funding access becomes harder and harder. We should all be concerned about the ramifications of not having volunteer groups around. Ones like Toot4Tucker. If that goes it will be a huge gap in the welfare of our communities.''
He said with the Matariki event in Kaiapoi being cancelled next month, it's obvious the funding is becoming harder and harder to find.
''The money to run community events like this has to come from somewhere, but where?''
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mirror
3 minutes ago
- Daily Mirror
Little-known site sees Marc Jacobs' 'perfect summer perfume' slashed to £33
If you've been looking for a new signature scent, Marc Jacobs' Dot, which shoppers say is perfect for summer, is now £33 instead of £99 thanks to this hidden gem savings site Purchasing a new fragrance requires a lot of thought and can be a real investment, especially if you're looking at designer fashion house perfumes that come with near-£100 price tags, if not even more. Luckily, if you are on the lookout for a signature scent, little-known savings site, Boop Beauty, has just slashed Marc Jacobs' Dot Eau de Parfum from £99 to £32.99 - that's a huge 67% discount! Dot is an iconic feel-good fragrance featuring notes of red berries, dragonfruit, and honeysuckle, which add a sweet, refreshing, summer touch. The soft floral notes of jasmine and orange blossom, with a hint of coconut water, give it a light, tropical feel that makes it perfect for summertime. Inspired by Marc Jacobs' iconic polka dots, the bottle features a gorgeous red-and-black spotted design with oversized butterfly wings for a playful touch. Not to mention, right on trend for this season. The gold coil around the neck adds a touch of luxe, making it a standout on any dressing table or shelf. Whether you're gifting someone special or treating yourself, Dot is the kind of perfume that feels like summer in both scent and style. Boop is not the only place where this summery scent is discounted. Currently, Boots is offering a huge 50% off, too, bringing the price down from £99 to £49. And if you're looking for further wallet-friendly fragrances, . Jimmy Choo's popular Flash Eau de Parfum, praised by shoppers for its long-lasting wear and feminine smell, is currently available for less than £25 in a limited-time flash sale on LookFantastic. Hundreds of shopper reviews praise Marc Jacobs Dot for its fruity and fresh scent. One happy shopper wrote, "It's a lovely, fresh summery fragrance that makes me feel warm and relaxed." A second added: "I have liked other Marc Jacob's so decided to give this one a try and I am certainly not disappointed I love the top on the bottle and the perfume is not like anything I've bought before, really like it." The only criticisms came from a few shoppers who claimed Dot does not last quite as long on the skin as some of Marc Jacobs' other fragrances, like his cult-favourite Daisy perfumes.


Glasgow Times
3 minutes ago
- Glasgow Times
Three-drug therapy helps women with aggressive breast cancer live longer
The treatment could also delay the need for gruelling chemotherapy, according to a trial. Researchers are hopeful the combination could become the 'new go-to option' for women with PIK3CA-mutated hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer. This mutation in the PIK3CA gene causes cells to divide and replicate uncontrollably. The final results from the INAVO120 study, led by experts at The Institute of Cancer Research, London, and the Royal Marsden NHS Foundation Trust, have been published in the New England Journal of Medicine and presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The trial included 325 patients from across 28 countries. More than half had metastatic breast cancer that had spread to three or more organs and the majority had already had chemotherapy. Researchers used a blood test known as a liquid biopsy, which detects tumour DNA in the blood, to test for the PIK3CA mutation. Of the total, 161 were given a three-drug combination comprising two targeted drugs – palbociclib, a type of cancer growth blocker, and a new drug called inavolisib, which blocks the activity of the PI3K protein – as well as the hormone therapy fulvestrant. The placebo group, which included 164 patients, was given a dummy pill plus palbociclib and fulvestrant. The study found the median overall survival in the inavolisib group was 34 months, compared with 27 months in the placebo group. The three-drug therapy also delayed disease progression by 17.2 months, compared with 7.3 months in the placebo group, with patients also able to delay chemotherapy treatment by almost two years longer. The latest results come after previous analysis of the study, published in October, showed the three-drug therapy delayed disease progression by an average of 15 months compared with 7.3 months in the placebo group. Lead author Nick Turner, a professor of molecular oncology at The Institute of Cancer Research, London, and consultant medical oncologist at The Royal Marsden NHS Foundation Trust, said: 'The key findings from this study showed that the inavolisib-based therapy not only helped patients live longer but it more than doubled the time before their cancer progressed or worsened. 'It also gave them more time before needing subsequent chemotherapy which we know is something that patients really fear and want to delay for as long as possible. 'These results give us confidence that this treatment could become the new go-to option for patients who have HR+, HER2- breast cancer with a PIK3CA mutation, as it has shown significant improvements in both survival and quality of life.' It is estimated that about 55,000 women are diagnosed with breast cancer in the UK every year, some 70% of whom will have HR+, HER2- breast cancer. PIK3CA mutations are found in 35-40% of HR+ breast cancers. The three-drug therapy of inavolisib, palbociclib and fulvestrant is not approved in the UK. However, the combination of palbociclib and fulvestrant has been available as an option for patients with certain types of breast cancer on the NHS since 2022. Prof Kristian Helin, chief executive of The Institute of Cancer Research, London, added: 'If we are to continue improving cancer survival rates, we need to tackle treatment resistance head on. 'This research demonstrates how this triple combination approach effectively shuts down cancer's escape routes, giving people with metastatic breast cancer the opportunity to live well for longer. 'One of the challenges with combination therapies is ensuring the right drug dosages and understanding their individual effects. 'It is extremely encouraging that this study not only demonstrates the effectiveness of this approach but also shows that the therapy was generally well tolerated by patients.' Reacting to the findings, Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said: 'This is a significant breakthrough and we're proud that it builds on a series of discoveries that our funded scientists have been making at the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, since it opened 25 years ago. 'We now hope to see this new combination therapy can be licensed by the MHRA (Medicines and Healthcare Products Regulatory Agency) and assessed by Nice (the National Institute for Health and Care Excellence) and the Scottish Medicine Council as soon as possible so that it can reach the NHS patients who could benefit from it.'
&w=3840&q=100)

Business Standard
4 minutes ago
- Business Standard
French Open stars tweak match slots to catch the Champions League final
The French Open isn't the only sports event in Europe drawing attention from tennis players: The Champions League final will decide the continent's best soccer club, and one of the two teams involved Saturday night is Paris Saint-Germain, whose stadium is a couple of blocks from Roland-Garros. Count Novak Djokovic among those rooting for PSG against Italy's Inter Milan, and he hoped to be able to tune in on TV to watch the big clash that'll be held in Munich, Germany. So Djokovic made that preference known to the people in charge of arranging the program at the clay-court Grand Slam tournament he's won three times a common practice, especially among the sport's elite. They often ask to be scheduled at a certain time. Or to avoid a certain time. I will definitely watch it if I'm not playing (in the) night session. Yeah, that will be nice, Djokovic said with a big smile. FYI, Roland-Garros schedule. Hint, hint. Except his plea went unheeded: When Saturday's order of play was released Friday, 24-time major champion Djokovic's third-round match against Filip Misolic was the one picked for under the lights at Court Philippe-Chatrier due to begin at 8:15 p.m. local time, 45 minutes before Inter Milan vs. PSG starts. Others who begged off from competing at that hour got their wish. Although one, Arthur Fils, the 14th-seeded Frenchman who grew up near Paris and is a big PSG fan, wound up pulling out of the tournament because of a back injury after being placed in an afternoon match against No. 17 Andrey Rublev. We have many requests from players every day, tournament director Amlie Mauresmo said. There's no fixed rule. We try to accommodate everyone as much as possible. That includes requests from players, broadcasters and spectators. ... It's a real puzzle, I won't lie. Coco Gauff said she doesn't often ask for a certain time slot, but when she does, it's usually related to competing in singles and doubles on the same day (the American won the French Open doubles title last year but isn't playing doubles this time). The 2023 U.S. Open champion, who is currently No. 2 in singles, has noticed that events tend to listen more to elite players than others. If you're ranked a little bit higher, they'll hear more of your input, for sure, Gauff said. To be honest, I think it's rightfully deserved. I feel like if you do well on tour, win so many tournaments, you should have a little bit more priority when it comes to that. Except even the very best of the best don't always have success with these sorts of things. Madison Keys, who was the U.S. Open runner-up in 2017 and won the Australian Open in January, knows what it's like to be ignored. Sometimes the request goes (in), they write it down, and they say, OK,' but then don't do anything about it, Keys said. I really think that it's just kind of up to what the tournament wants, what TV wants, things like that, she added. Sometimes you kind of get what you ask for. And other times, you get the complete opposite. Just ask Djokovic. Whatever they schedule me, I have to accept, he said earlier this season. I think I earned my right to ... (communicate) with the tournament management, where I can express what I would like, depending on a given day, depending on the opponent.